Literature DB >> 27866277

Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.

Shalvaree Vaidya1,2, Clare L Hibbert3, Elizabeth Kinter4, Stefan Boes3.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.
OBJECTIVES: We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.
RESULTS: The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.
CONCLUSION: More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.

Entities:  

Keywords:  Cost; Cost triggers; Economic impact; Financial burden; Idiopathic pulmonary fibrosis; Systematic review

Mesh:

Year:  2016        PMID: 27866277     DOI: 10.1007/s00408-016-9960-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  22 in total

Review 1.  Lung transplant in idiopathic pulmonary fibrosis.

Authors:  Timothy J George; George J Arnaoutakis; Ashish S Shah
Journal:  Arch Surg       Date:  2011-10

Review 2.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.

Authors:  Steven D Nathan; Paul W Noble; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

Review 3.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

4.  An Analysis of Us Medicare Beneficiaries: Burden of Direct Medical Costs in Patients With Idiopathic Pulmonary Fibrosis.

Authors:  S Y Chen; H R Collard; W S Yeh; Q Li; Y C Lee; A Wang; G Raghu
Journal:  Value Health       Date:  2014-10-26       Impact factor: 5.725

Review 5.  Comprehensive care of the patient with idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Sally McLaughlin; Harold R Collard
Journal:  Curr Opin Pulm Med       Date:  2011-09       Impact factor: 3.155

Review 6.  The burden of idiopathic pulmonary fibrosis: an unmet public health need.

Authors:  Augustine S Lee; Isabella Mira-Avendano; Jay H Ryu; Craig E Daniels
Journal:  Respir Med       Date:  2014-04-13       Impact factor: 3.415

Review 7.  The impact of emphysema in pulmonary fibrosis.

Authors:  Vincent Cottin
Journal:  Eur Respir Rev       Date:  2013-06-01

Review 8.  Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature.

Authors:  Kristin D Kistler; Luba Nalysnyk; Philip Rotella; Dirk Esser
Journal:  BMC Pulm Med       Date:  2014-08-16       Impact factor: 3.317

Review 9.  The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.

Authors:  Emma Loveman; Vicky R Copley; Jill L Colquitt; David A Scott; Andy J Clegg; Jeremy Jones; Katherine M A O'Reilly; Sally Singh; Claudia Bausewein; Athol Wells
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-19       Impact factor: 2.483

10.  Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.

Authors:  Edward C F Wilson; Ludmila Shulgina; Anthony P Cahn; Edwin R Chilvers; Helen Parfrey; Allan B Clark; Orion P Twentyman; Andrew M Wilson
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

View more
  4 in total

1.  Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Authors:  Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

2.  Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.

Authors:  Mariann I Lassenius; Iiro Toppila; Nora Pöntynen; Laura Kasslin; Jaana Kaunisto; Maritta Kilpeläinen; Tarja Laitinen
Journal:  Eur Clin Respir J       Date:  2019-12-17

3.  Increased respiratory morbidity in individuals with interstitial lung abnormalities.

Authors:  Nils Hoyer; Laura H Thomsen; Mathilde M W Wille; Torgny Wilcke; Asger Dirksen; Jesper H Pedersen; Zaigham Saghir; Haseem Ashraf; Saher B Shaker
Journal:  BMC Pulm Med       Date:  2020-03-19       Impact factor: 3.317

4.  Cost drivers in the pharmacological treatment of interstitial lung disease.

Authors:  Phillen Nozibuyiso Maqhuzu; Michael Kreuter; Thomas Bahmer; Nicolas Kahn; Martin Claussen; Rolf Holle; Larissa Schwarzkopf
Journal:  Respir Res       Date:  2021-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.